Analysts Offer Insights on Healthcare Companies: Amgen Inc (AMGN) and Aquestive Therapeutics Inc (AQST)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen Inc (NASDAQ:AMGN) and Aquestive Therapeutics Inc (NASDAQ:AQST) with bullish sentiments.

Amgen Inc (AMGN)

Jefferies analyst Michael Yee maintained a Buy rating on Amgen Inc today and set a price target of $220. The company’s shares opened today at $196.64, close to its 52-week high of $201.23.

According to TipRanks.com, Yee is a 4-star analyst with an average return of 6.8% and a 55.5% success rate. Yee covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Rubius Therapeutics Inc, and Vertex Pharmaceuticals.

Amgen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $203.11, representing a 3.3% upside. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $206 price target.

.

See today’s analyst top recommended stocks >>

Aquestive Therapeutics Inc (AQST)

BMO Capital analyst Gary Nachman maintained a Buy rating on Aquestive Therapeutics Inc today and set a price target of $26. The company’s shares opened today at $15.73.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 10.8% and a 55.4% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Bausch Health Companies Inc, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aquestive Therapeutics Inc with a $26 average price target, a 65.3% upside from current levels. In a report issued on August 20, RBC Capital also initiated coverage with a Buy rating on the stock with a $23 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts